GlassScriptPhysician profile
Farnoush Jamali
NPI 1518293588
$772.73
in general payments reported to CMS, 2019-2025
11 companies · $91.72 in 2025
The $91.72 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.52 · 2020: $22.21 · 2021: $144 · 2022: $108 · 2023: $118 · 2024: $192 · 2025: $91.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $220.77 | 2021-2025 | Kristalose |
| Cranial Technologies, INC | $145.46 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $119.26 | 2020-2023 | Bexsero, Pediarix |
| Merck Sharp & Dohme LLC | $66.93 | 2019-2024 | Vaxneuvance, Gardasil 9, M-M-R II |
| Sanofi-Aventis U.S. LLC | $45.75 | 2024 | |
| Alk-Abello, INC | $42.97 | 2025 | Neffy |
| Sobi, INC | $42.55 | 2021-2022 | |
| Sanofi Pasteur INC. | $40.41 | 2021-2024 | |
| Hikma Pharmaceuticals USA | $17.90 | 2019 | |
| Adlon Therapeutics L.P. | $15.90 | 2019 | |
| Circassia INC. | $14.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farnoush Jamali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.